Risk - adapted chemotherapy in advanced - stage Hodgkin{u2019}s Lymphoma / Wageeh Elsebaey Mohamed Saied ; Supervised Nasr Mohamed M. Ali Allahloubi , Sameh Sayed Ahmed Shamaa , Thoraya Mohamed Abdelhamid

By:

Wageeh Elsebaey Mohamed Saied

Contributor(s):

Material type: Text

TextLanguage: English Publication details: Cairo : Wageeh Elsebaey Mohamed Saied , 2014Description: 194 P. : facsimiles ; 25cmOther title:

العلاج الكيماوى للمراحل المتقدمة من أورام الغدد الليمفاوية(هودجكن) طبقا لعوامل الخطورة [Added title page title]

Subject(s):

Available additional physical forms:

Issued also as CD

Dissertation note: Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Medical Oncology Summary: Background and Aim of the Work: Hodgkin{u2019}s Lymphoma is an uncommon malignant tumor of the lymphatic system represents about 10% of all Lymphomas, one of the first cancers to be cured by combination chemotherapy. A prospective study to test the efficacy of the German regimen BEACOPP baseline in the treatment of the advanced stage poor risk Hodgkin's lymphoma and to compare the results with the ABVD regimen as regard response, survival and toxicity. Patients and Methods: This is a prospective phase II randomized trial that has been conducted on 60 cases with advanced-stage Hodgkin's Lymphoma ,The patients were randomized into two arms, 30 patients in each arm, Arm A: received ABVD regimen, Arm B: received BEACOPP(base-line)regimen for 6-8 cycles in each arm. All patients were subjected to close follow-up to assess the response to treatment and possible complications. Results: Median age of the patients at time of diagnosis in arm A was 43 years, and in arm B was 39 years, In the treatment Arm A (ABVD), complete response (CR) was achieved in 18 cases (60%), partial response (PR) was achieved in 8 cases (26.7%), stationary response was achieved in two cases (6.7%) and PD (progressive disease) in two cases (6.7%)

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Copy number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2014.Wa.R (Browse shelf(Opens below))		Not for loan		01010110066905000
CD - Rom	مخـــزن الرســائل الجـــامعية - البدروم	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.Ph.D.2014.Wa.R (Browse shelf(Opens below))	66905.CD	Not for loan		01020110066905000

Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Medical Oncology

Background and Aim of the Work: Hodgkin{u2019}s Lymphoma is an uncommon malignant tumor of the lymphatic system represents about 10% of all Lymphomas, one of the first cancers to be cured by combination chemotherapy. A prospective study to test the efficacy of the German regimen BEACOPP baseline in the treatment of the advanced stage poor risk Hodgkin's lymphoma and to compare the results with the ABVD regimen as regard response, survival and toxicity. Patients and Methods: This is a prospective phase II randomized trial that has been conducted on 60 cases with advanced-stage Hodgkin's Lymphoma ,The patients were randomized into two arms, 30 patients in each arm, Arm A: received ABVD regimen, Arm B: received BEACOPP(base-line)regimen for 6-8 cycles in each arm. All patients were subjected to close follow-up to assess the response to treatment and possible complications. Results: Median age of the patients at time of diagnosis in arm A was 43 years, and in arm B was 39 years, In the treatment Arm A (ABVD), complete response (CR) was achieved in 18 cases (60%), partial response (PR) was achieved in 8 cases (26.7%), stationary response was achieved in two cases (6.7%) and PD (progressive disease) in two cases (6.7%)

Issued also as CD

There are no comments on this title.

to post a comment.